A drug delivery system for percutaneous coronary intervention

A drug delivery system and coronary artery technology, applied in the field of medicine, to increase the activity of adenosine kinase, improve the metabolism of adenosine, and improve the protective effect of myocardial reperfusion

Active Publication Date: 2021-07-16
ZHONGSHAN HOSPITAL FUDAN UNIV
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] In order to overcome the problems caused by the above-mentioned single-component adenosine treatment, the inventors conducted in-depth research on the physiological metabolic pathway of adenosine in the body, and unexpectedly found that adenosine kinase (adenosine kinase, ADK) can significantly intervene and regulate adenosine Physiological metabolism in the body, and can also produce new functions

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A drug delivery system for percutaneous coronary intervention
  • A drug delivery system for percutaneous coronary intervention
  • A drug delivery system for percutaneous coronary intervention

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0037] The construction of embodiment 1 mouse model

[0038] 1.1 Experimental animals

[0039] Prepare 8-10-week-old adult male C57BL / 6 ADK-Cre mice (ADK-Cre) mice, weighing 24.5g±0.8g; prepare 8-10-week-old male C57BL / 6 mice (Wildtype, WT) Mice, weighing 24.2g±1.1g, were used as a control group. The myocardial-specific ADK knockout (ADK-Cre) mouse model of acute myocardial infarction used in the experiment was constructed by the Animal Experiment Center of Zhongshan Hospital Affiliated to Fudan University; the wild-type mouse (WT) acute myocardial infarction model was established by Zhongshan Hospital Affiliated to Fudan University Provided by the Animal Experiment Center, the purchased mice were raised in the SPF animal room of the Public Health Clinical Center Affiliated to Fudan University. During the experiment, they were all raised in the SPF animal room of the Experimental Animal Center of Zhongshan Hospital Affiliated to Fudan University. After 3 days of adapting to ...

Embodiment 2

[0048] Embodiment 2 percutaneous coronary intervention

[0049] For myocardial ischemia-reperfusion (I / R), see the steps in Example 1, wherein the steps of simulating traditional adenosine injection and the adenosine + adenosine kinase percutaneous coronary intervention proposed by this patent are as follows:

[0050] (1) Traditional adenosine injection

[0051] Before step 6) of "drawing the slipknot" in Example 1, inject adenosine solution through the tail vein of the mice. 20mg of adenosine is dissolved in 50ml of physiological saline to form an adenosine solution.

[0052] (2) Adenosine + adenosine kinase injection

[0053] Before step 6) of "drawing the slipknot" in Example 1, inject adenosine solution through the tail vein of the mouse. Then inject and infuse 100 μg / ml human recombinant adenosine kinase physiological saline solution in the same route, the dose is 1 μg / kg body weight.

Embodiment 3

[0054] Embodiment 3 mouse model anatomy experiment

[0055] 3.1 Principle of Evan blue / TTC staining:

[0056] After coronary attention, Evans will enter the unligated coronary artery in the coronary system and stain the normal myocardium, while the ischemic area will not appear blue due to coronary artery obstruction;

[0057] As a fat-soluble light-sensitive complex, TTC (2,3,5-triphenyltetrazolium chloride) is the proton acceptor of the pyridine-nucleoside structural enzyme system in the respiratory chain, and reacts with dehydrogenase in normal tissues It is red, but the dehydrogenase activity in the ischemic tissue decreases and cannot react, so it will not change and appear pale.

[0058] 3.2 TTC solution preparation:

[0059] ①0.1M Na 2 HPO 4 : 14.2mg dissolved in 1L double distilled water;

[0060] ②0.1M NaH 2 PO 4 : 12mg dissolved in 1L double distilled water;

[0061] ③ Mix ① and ② solution, titrate to pH7.4;

[0062] ④ Dissolve 1g of TTC powder in 100ml of ③...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a drug delivery system for percutaneous coronary intervention, which comprises: adenosine; infusion consumables for adenosine infusion; used for catalyzing excessive adenosine metabolism in the body, and Adenosine kinase that activates the downstream AMPK pathway; infusion consumable for infusion of adenosine kinase. The drug delivery system can reduce the retention of adenosine after percutaneous coronary intervention in patients with adenosine kinase mutation or insufficient activity, increase the activity of adenosine kinase, thereby reducing myocardial reperfusion injury and improving the myocardial reperfusion protective effect of adenosine.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to a drug delivery system suitable for percutaneous coronary intervention for people with adenosine kinase mutation or insufficient activity, especially a drug delivery system suitable for acute myocardial infarction patients with adenosine kinase mutation or insufficient activity Adenosine and adenosine kinase combination drug delivery system for percutaneous coronary intervention. Background technique [0002] Acute myocardial infarction (AMI) is a serious cardiovascular disease. Percutaneous coronary intervention (PCI) has become one of the most important minimally invasive treatments for AMI. Clinical studies have shown that early recovery for AMI patients Lesioned myocardial blood flow can effectively reduce myocardial necrosis, prevent ventricular remodeling, reduce the incidence of arrhythmia, improve the long-term prognosis of cardiac function, and generally reduce the mo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K38/45A61K31/7076A61P9/10A61M5/14
CPCA61K31/7076A61K38/45A61M5/14A61K2300/00
Inventor 葛均波孙爱军王鹏
Owner ZHONGSHAN HOSPITAL FUDAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap